drugset
Drugs / TB-402
last change May 2012 re-read 2 minutes ago

TB-402

Monoclonal antibody targets F8 via inhibition

Developed for
venous thromboembolism
Investigated by
BioInvent International AB · ThromboGenics · Covance

Trials 4 · a red edge is where a trial was stopped

today NCT01344954 · Ph 2 NCT00793234 · Ph 2 NCT00618579 · Ph 1 NCT00612196 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00618579 Feb → Jun 2008 — ThromboGenics Completed No outcome recorded
Phase 1 NCT00612196 Mar → Oct 2007 — ThromboGenics Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01344954 Apr → Dec 2011 venous thromboembolism ThromboGenics Completed No outcome recorded
Phase 2 NCT00793234 Dec 2008 → Jan 2010 — ThromboGenics Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00612417 Background Jan → Mar 2008 — ThromboGenics Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as TB-402 “TB-402, a human monoclonal antibody that partially inhibits Factor VIII activity (FVIII:C), is being developed as a long-acting antithrombotic agent.” PMID 20637972 ↗ Jun 2010
4

NCT00793234 ↗

NCT01344954 ↗

NCT00612417 ↗

NCT00618579 ↗
Action Inhibit “TB-402, a human monoclonal antibody that partially inhibits Factor VIII activity (FVIII:C)” PMID 20637972 ↗ Jun 2010
1

“Coagulation factor VIII inhibitor” CHEMBL2109410 ↗
Modality Monoclonal antibody “TB-402, a human monoclonal antibody that partially inhibits Factor VIII activity (FVIII:C)” PMID 20637972 ↗ Jun 2010
Route Intravenous “TB-402 administered as a single intravenous bolus” PMID 20637972 ↗ Jun 2010
Target F8 “Coagulation factor VIII inhibitor” CHEMBL2109410 ↗